Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05989126 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)
A Phase 3 study, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 35
- Enrollment target
NCT05989126 is a Phase 3 study that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 35 participants.
The verdict
NCT05989126, a Phase 3 study, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 35 participants
- Enrollment target
Study Summary
Regeneron Pharmaceuticals developed a single-dose pre-filled syringe (PFS) to deliver 8 mg aflibercept. The PFS is a convenient device that contains the study medication that will be injected in your study eye. A PFS offers a sterile, single dose of study drug within the syringe; this eliminates the need for the retina specialist to prepare the injection syringe from a separate vial. This Phase IIIb study is focused on patients with diabetic macular edema (DME) and neovascular (wet) age-related macular degeneration (nAMD). The main aim of the study is to evaluate if the 8 mg aflibercept PFS allows for successful preparation and administration of 8 mg aflibercept by retina specialists. The study will also assess the safety of 8 mg aflibercept PFS use. Regeneron will use the information from the study to better understand if the PFS can be used safely and effectively by retina specialists to administer 8 mg aflibercept.
Interventions
- DRUG aflibercept 8 mg PFS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2024-04-15 |
| Est. Completion | 2024-05-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05989126
The ClinicalTrials.gov registry entry for NCT05989126 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which aflibercept 8 mg PFS is the first listed.
NCT05989126 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05989126 about?
NCT05989126 is a clinical study titled "Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)". Regeneron Pharmaceuticals developed a single-dose pre-filled syringe (PFS) to deliver 8 mg aflibercept. The PFS is a convenient device that contains the study medication that will be injected in your study eye. A PFS offers a sterile, single dose of study drug within the syringe; this eliminates the...
What is the current status of trial NCT05989126?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 35 participants. The study started on 2024-04-15. Estimated completion is 2024-05-31.
What interventions are being tested in trial NCT05989126?
The interventions under investigation include: aflibercept 8 mg PFS (DRUG).
Who is sponsoring clinical trial NCT05989126?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.